MBX Biosciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, MBX Biosciences sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
MBX Biosciences: 7 sponsored US clinical trials, 2 recruiting.
MBX Biosciences sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypoparathyroidism, with 2 trials.
Upper-quartile sponsor footprint
MBX Biosciences sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
NCT07142707
Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)
NCT07029412
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
NCT06531941
Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
NCT06465108
Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function
NCT06496217
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects
NCT06036784
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects
NCT05158335
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the MBX Biosciences pipeline
2 recruiting of 7 indexed (29% open); 4 completed (57%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Hypoparathyroidism (2 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
MBX Biosciences: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
MBX Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this MBX Biosciences page
7 registered trials is a research-attention snapshot, not an endorsement of MBX Biosciences or any single study.
- 2 of MBX Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hypoparathyroidism is the condition MBX Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypoparathyroidism trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
MBX Biosciences pipeline card: 7 registered trials from official public datasets.Report a data error.